On September 23, 2021, Parallax Health Sciences, Inc. executed an Executive Agreement for the appointment of Ms. Sonia Choi as the Company’s interim Chief Executive Officer effective September 14, 2021, pursuant to a resolution of the board of directors dated September 15, 2021. The Executive Agreement replaces any other agreement between Ms. Choi and the Company or any of its subsidiaries, is for an initial term of one (1) year, and provides a base compensation of $185,000 per annum. The Executive Agreement also provides for various performance bonuses, and customary employee benefits, as well as performance-based stock options to purchase shares of the Company's Common Stock at an exercise price of $0.052 for a period of five (5) years from the date of grant, to be granted upon satisfactory completion of performance events. Ms. Choi is a highly experienced executive who combines analytical business strategies with results-driven creativity to identify new opportunities to drive growth. She has played key roles in innovative startup companies, and has launched new initiatives for small e-commerce companies.  She has also led successful business development and marketing campaigns for NASDAQ traded companies.  In addition, Ms. Choi has assisted several startup companies in securing Series A & Series B funding, and has commanded D&I initiatives in the field of technology.